Latest Headlines

  1. SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization Of DISCERN, Highly Accurate, Minimally Invasive Alzheimer’s Disease Diagnostic Test 8/9/2022

    SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN, a minimally invasive diagnostic test to identify AD in people living with dementia.

  2. T2 Biosystems To Explore Potential To Develop Rapid Molecular Diagnostic Test For Monkeypox Virus 8/9/2022

    T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility.

  3. Metabolon Announces Joint Development Agreement With Mayo Clinic To Create New Diagnostic Tests 8/9/2022

    Metabolon, Inc., the global leader in metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a joint development agreement with Mayo Clinic to develop novel metabolomic biomarker diagnostic tests.

  4. Deep Bio Successfully Integrates DeepDx® Prostate Algorithm Into HALO AP® Platform From Indica Labs 8/9/2022

    Deep Bio, a company concentrating on SaMD (Software as a Medical Device) for digital pathology, offering clinically validated, AI-based DeepDx® algorithms, and Indica Labs, a leading provider of computational pathology software and services, are excited to announce the successful integration of the DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs.

  5. Imspex Diagnostics Announces BreathSpec® Instrument 8/9/2022

    Imspex Diagnostics Ltd today announced that it has received CE mark for its BreathSpec® instrument for the detection of COVID-19 using non-invasive breath testing and analysis having met the requirements of the European In-Vitro Diagnostics Directive (98/79/EC).

  6. BD, Labcorp Collaborate To Develop Flow Cytometry-Based Companion Diagnostics For Matching Patients With Treatments 8/9/2022

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.

  7. Alercell® To Distribute AmoyDx® Ros1 Gene Fusion Detection Kit 8/8/2022

    Alercell® announced today that it has started the distribution of AmoyDx ROS1 Gene Fusion Detection Kit. Part of the master distribution agreement with Amoy Diagnostics Co., Ltd (AmoyDx), signed last month.

  8. Revolutionizing Healthcare Testing: 1health Unveils Next Generation Diagnostic Platform That Enables Precision Medicine At Scale 8/3/2022

    1health.io Inc. (“1health”), an industry-leading healthcare tech company that empowers laboratories to make diagnostic testing accessible and affordable at scale, announces the launch of its Next Generation Diagnostic Platform.

  9. Automated Dried Spot Sampling And Analysis System Redefines Workflow 8/3/2022

    Thermo Fisher Scientific Inc., the world leader in serving science, enables clinical research, toxicology and anti-doping laboratories performing dried spot sampling and analysis to utilize a new automated sample prep and ultra-high-performance liquid chromatography (UHPLC) system to improve efficiency, robustness, sensitivity and sample traceability.

  10. CirrusDx Acquires Dascena's Texas Laboratory Business, Expanding Infectious Disease Portfolio 8/3/2022

    Cirrus Dx, Inc. ("CirrusDx"), an infectious disease diagnostics and laboratory company, announces the acquisition of Dascena Inc.'s Houston-based laboratory business, Dascena Labs, LLC ("Dascena Labs").